Form 4: Jasper Therapeutics Director Acquires Stock Options
SEC Form 4
Christian Nolet, a director of Jasper Therapeutics, acquired 7,500 stock options on June 6, 2024, at an exercise price of $25.41.
Summary
- Christian Nolet, a director of Jasper Therapeutics, Inc., filed a Form 4 on June 10, 2024, reporting a transaction.
- On June 6, 2024, Nolet acquired 7,500 stock options with an exercise price of $25.41.
- The options become exercisable on June 6, 2025, and expire on June 6, 2034.
- Following the transaction, Nolet directly owns 7,500 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Stakeholder Impact
- Shareholders can use this information to understand the actions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 2024-05-29 | Power of Attorney executed. |
| 2024-06-06 | Date of earliest transaction (acquisition of stock options). |
| 2024-06-06 | Stock options become exercisable. |
| 2024-06-10 | Form 4 filing date. |
| 2024-06-06 | Stock options expire. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.